SL Science Holding Ltd

SLBT | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.21

+$0.01 (+0.83%)

Nov 2, 2026, 10:14 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.83%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

16.6

+2.0 pts

Fundamentals Weak

Market Sentiment Neutral

Moat None

Sector Rank #1011/1028 (Top 98%)

Full Analysis

Key Statistics

Market Data

Market Cap $675.72M

1D Range

1.20 1.23

52W Range

1.15 11.02

Valuation (TTM)

PE -2.82

PB 304.45

EV/EBITDA -433,393.81

Valuation (NTM)

Forward PE N/A

Forward PEG 0.00

Price Target $0.00

Cash Flow

FCF Yield 0.0%

SBC Adj. FCF Yield 0.0%

SBC Impact N/A

Margins

Gross Margin 35.3%

Operating Margin -142.4%

FCF Margin -39.9%

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y N/A | N/A

FCF 3Y | 5Y N/A | N/A

Returns

ROA -135.6%

ROE -95.4%

ROIC -153.7%

Financial Health

Net Cash

$1.26M

Current Ratio 3.05

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company’s products include SL bio’s milk-derived exosome essence, SL bio’s tangerine-derived extract, and the Mi...

Sector Healthcare

Industry Biotechnology

Employees 15

IPO Date Feb 5, 2025

Website www.sl-bio.com

Fiscal Year January - December

Full Company Profile

Latest News

2 months ago · seekingalpha.com

SL Science: A $1.15 Billion Valuation Built On Preclinical Promises

SL Science Holding Limited is rated Sell due to an unsustainable $1.15B valuation built on a strictly preclinical pipeline. SLBT's flagship Gamma Delta T cell therapy targets aggressive solid tumors but has not entered human trials, with a very low probability of success. With only $9M in cash, a $3.82M annual loss, and going-concern doubts, imminent dilution is almost certain without a major partnership.

2 months ago · globenewswire.com

SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced that its management team rang Nasdaq bell at the Nasdaq MarketSite in Times Square, New York, to celebrate its first quarter as a publicly traded company.

2 months ago · globenewswire.com

SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform

TAIPEI, Taiwan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in innovative cellular and gene therapies, today highlighted the filing of a new Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA). The DMF, filed under number 044612, covers exosomes derived from Gamma Delta T (GDT) cells. It was filed by JY BioMed Co., Ltd. (“JY BioMed”), the intellectual property holder of the GDT platform and SL Science's licensor.